HK1173441A1 - Phenyloxadiazole erivatives as pgds inhibitors - Google Patents
Phenyloxadiazole erivatives as pgds inhibitorsInfo
- Publication number
- HK1173441A1 HK1173441A1 HK13100596.3A HK13100596A HK1173441A1 HK 1173441 A1 HK1173441 A1 HK 1173441A1 HK 13100596 A HK13100596 A HK 13100596A HK 1173441 A1 HK1173441 A1 HK 1173441A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- phenyloxadiazole
- erivatives
- pgds inhibitors
- pgds
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24969309P | 2009-10-08 | 2009-10-08 | |
| FR1056094 | 2010-07-26 | ||
| PCT/US2010/051727 WO2011044307A1 (en) | 2009-10-08 | 2010-10-07 | Phenyloxadiazole derivatives as pgds inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1173441A1 true HK1173441A1 (en) | 2013-05-16 |
Family
ID=43606440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK13100596.3A HK1173441A1 (en) | 2009-10-08 | 2013-01-15 | Phenyloxadiazole erivatives as pgds inhibitors |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US9469627B2 (xx) |
| EP (1) | EP2486024B1 (xx) |
| JP (2) | JP5753176B2 (xx) |
| KR (1) | KR101701135B1 (xx) |
| CN (3) | CN102666508A (xx) |
| AR (1) | AR078552A1 (xx) |
| AU (1) | AU2010303439B2 (xx) |
| BR (1) | BR112012007635B1 (xx) |
| CA (1) | CA2776242C (xx) |
| DK (1) | DK2486024T3 (xx) |
| ES (1) | ES2543011T3 (xx) |
| HK (1) | HK1173441A1 (xx) |
| IL (1) | IL218967A (xx) |
| MA (1) | MA33725B1 (xx) |
| MX (1) | MX2012003021A (xx) |
| NZ (1) | NZ599099A (xx) |
| RU (2) | RU2572608C2 (xx) |
| SG (1) | SG179199A1 (xx) |
| TW (1) | TWI508960B (xx) |
| UY (1) | UY32938A (xx) |
| WO (1) | WO2011044307A1 (xx) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2776242C (en) | 2009-10-08 | 2014-09-02 | Sanofi | Phenyloxadiazole derivatives as pgds inhibitors |
| US9320723B2 (en) * | 2010-05-03 | 2016-04-26 | University Of Rochester | Methods of treating thyroid eye disease |
| CN108430992A (zh) | 2015-12-17 | 2018-08-21 | 阿斯特克斯医疗公司 | 作为h-pgds抑制剂的喹啉-3-甲酰胺 |
| JOP20190072A1 (ar) | 2016-10-13 | 2019-04-07 | Glaxosmithkline Ip Dev Ltd | مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم |
| HUE064642T2 (hu) * | 2017-05-22 | 2024-04-28 | Egyt Gyogyszervegyeszeti Gyar | Eljárás ozanimod elõállítására |
| TW201908311A (zh) | 2017-06-13 | 2019-03-01 | 英商葛蘭素史克智慧財產發展有限公司 | 化合物 |
| EP3724197A1 (en) | 2017-12-13 | 2020-10-21 | GlaxoSmithKline Intellectual Property Development Ltd | Fused pyridines which act as inhibitors of h-pgds |
| AR117006A1 (es) | 2018-11-08 | 2021-07-07 | Glaxosmithkline Ip Dev Ltd | Compuesto de 1,3-azol sustituido, composición farmacéutica que lo comprende y su uso para la fabricación de un medicamento |
| KR20230027059A (ko) | 2020-06-19 | 2023-02-27 | 사토 세이야쿠 가부시키가이샤 | H－pgds를 저해하는 축환 화합물 |
| EP4450502A1 (en) * | 2021-12-17 | 2024-10-23 | Sato Pharmaceutical Co., Ltd. | Azaindole derivative inhibiting h-pgds |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5176132A (en) | 1989-05-31 | 1993-01-05 | Fisons Plc | Medicament inhalation device and formulation |
| DE10117823A1 (de) * | 2001-04-10 | 2002-10-17 | Merck Patent Gmbh | Oxalsäurederivate |
| AU2003221325A1 (en) * | 2002-03-19 | 2003-09-29 | Ono Pharmaceutical Co., Ltd. | Carboxyoic acid compounds and drugs containing the compounds as the acive ingredient |
| KR20050035885A (ko) | 2002-08-16 | 2005-04-19 | 아벤티스 파마슈티칼스 인크. | 마이크로솜성 프로스타글란딘 ｅ 신타제 또는 조혈성 프로스타글란딘 ｄ 신타제의 활성을 감소시키는 능력에 대해 화합물 또는 제제를 검정하는 방법 |
| GB0222023D0 (en) | 2002-09-21 | 2002-10-30 | Aventis Pharma Ltd | Inhaler |
| WO2005094805A1 (ja) | 2004-04-01 | 2005-10-13 | Institute Of Medicinal Molecular Design. Inc. | イミン誘導体及びアミド誘導体 |
| ES2342082T3 (es) * | 2004-04-21 | 2010-07-01 | Schering Corporation | Antagonistas de receptores a2a de adenosina de pirazolo(4,3-e)-1,2,4-triazolo(1,5-c)pirimidina. |
| JP5209181B2 (ja) * | 2005-03-15 | 2013-06-12 | 富士フイルム株式会社 | 化合物、組成物、位相差板、楕円偏光板および液晶表示装置 |
| TW200720255A (en) | 2005-07-13 | 2007-06-01 | Taiho Pharmaceutical Co Ltd | Benzoimidazole compound capable of inhibiting prostaglandin d synthetase |
| JP2007051121A (ja) * | 2005-07-22 | 2007-03-01 | Taiho Yakuhin Kogyo Kk | プロスタグランジンｄ合成酵素を阻害するピリミジン化合物 |
| CN100556905C (zh) * | 2005-09-08 | 2009-11-04 | 国家南方农药创制中心江苏基地 | 吡唑酰胺类化合物及其中间体和以该类化合物为活性成分的有害生物防治剂 |
| WO2007039177A2 (en) | 2005-09-29 | 2007-04-12 | Sanofi-Aventis | Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals |
| PE20070589A1 (es) * | 2005-10-04 | 2007-06-22 | Aventis Pharma Inc | Compuestos de pirimidina amida como inhibidores de pgds |
| EP2129660A2 (en) | 2006-12-19 | 2009-12-09 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
| WO2008104869A1 (en) * | 2007-02-26 | 2008-09-04 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
| AU2008232771B2 (en) | 2007-03-30 | 2012-12-20 | Sanofi-Aventis | Pyrimidine hydrazide compounds as PGDS inhibitors |
| GB0706793D0 (en) | 2007-04-05 | 2007-05-16 | Evotec Ag | Compounds |
| AR074776A1 (es) * | 2008-12-18 | 2011-02-09 | Sanofi Aventis | Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente |
| WO2010080653A1 (en) | 2009-01-12 | 2010-07-15 | The Government Of U.S.A, As Represented By The Secretary Of The Navy | Composite electrode structure |
| CA2776242C (en) * | 2009-10-08 | 2014-09-02 | Sanofi | Phenyloxadiazole derivatives as pgds inhibitors |
-
2010
- 2010-10-07 CA CA2776242A patent/CA2776242C/en active Active
- 2010-10-07 AR ARP100103650A patent/AR078552A1/es unknown
- 2010-10-07 MX MX2012003021A patent/MX2012003021A/es not_active Application Discontinuation
- 2010-10-07 CN CN201080055808XA patent/CN102666508A/zh active Pending
- 2010-10-07 SG SG2012018933A patent/SG179199A1/en unknown
- 2010-10-07 CN CN201710240652.6A patent/CN106943407A/zh active Pending
- 2010-10-07 JP JP2012533302A patent/JP5753176B2/ja active Active
- 2010-10-07 NZ NZ599099A patent/NZ599099A/xx unknown
- 2010-10-07 RU RU2012118756/04A patent/RU2572608C2/ru active
- 2010-10-07 EP EP20100765724 patent/EP2486024B1/en active Active
- 2010-10-07 TW TW099134129A patent/TWI508960B/zh active
- 2010-10-07 ES ES10765724.9T patent/ES2543011T3/es active Active
- 2010-10-07 WO PCT/US2010/051727 patent/WO2011044307A1/en active Application Filing
- 2010-10-07 DK DK10765724.9T patent/DK2486024T3/en active
- 2010-10-07 RU RU2015151129A patent/RU2015151129A/ru not_active Application Discontinuation
- 2010-10-07 AU AU2010303439A patent/AU2010303439B2/en active Active
- 2010-10-07 KR KR1020127008972A patent/KR101701135B1/ko active IP Right Grant
- 2010-10-07 BR BR112012007635-3A patent/BR112012007635B1/pt active IP Right Grant
- 2010-10-07 CN CN201711114032.4A patent/CN107875155A/zh active Pending
- 2010-10-08 UY UY0001032938A patent/UY32938A/es not_active Application Discontinuation
-
2012
- 2012-04-01 IL IL218967A patent/IL218967A/en active IP Right Grant
- 2012-04-04 US US13/439,511 patent/US9469627B2/en active Active
- 2012-05-04 MA MA34835A patent/MA33725B1/fr unknown
-
2013
- 2013-01-15 HK HK13100596.3A patent/HK1173441A1/xx unknown
-
2015
- 2015-05-20 JP JP2015102335A patent/JP5897186B2/ja active Active
-
2016
- 2016-09-07 US US15/258,892 patent/US9937175B2/en active Active
-
2018
- 2018-02-23 US US15/903,337 patent/US20190000845A1/en not_active Abandoned
- 2018-09-20 US US16/137,241 patent/US20190262338A1/en not_active Abandoned
-
2022
- 2022-11-22 US US17/992,553 patent/US20230190747A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1173441A1 (en) | Phenyloxadiazole erivatives as pgds inhibitors | |
| IL216145A0 (en) | Dihydropyrimidinones for use as bace2 inhibitors | |
| PL2393812T3 (pl) | Podstawione spiroamidy jako modulatory B1R | |
| GB201004311D0 (en) | New enzyme inhibitor compounds | |
| EP2567191A4 (en) | LEVEL LIGHTED | |
| ZA201108131B (en) | Dihydroorotate- dehydrogenasee inhibitors as virostatic compounds | |
| GB0907350D0 (en) | Methods | |
| ZA201107962B (en) | Borinic compositions | |
| EP2408473A4 (en) | METHODS OF VACCINATION | |
| GB0901001D0 (en) | Methods | |
| IL218500A0 (en) | Apogossypolone derivatives as anticaner agents | |
| GB0900555D0 (en) | New methods | |
| AU2009101227A4 (en) | Easy kneel | |
| GB0906306D0 (en) | Culture | |
| GB0906307D0 (en) | Culture | |
| GB0906301D0 (en) | Culture | |
| GB0906302D0 (en) | Culture | |
| GB0906303D0 (en) | Culture | |
| GB0906304D0 (en) | Culture | |
| GB0906305D0 (en) | Culture | |
| GB0906308D0 (en) | Culture | |
| GB0906309D0 (en) | Culture | |
| GB0906311D0 (en) | Culture | |
| GB0906310D0 (en) | Culture | |
| GB0915927D0 (en) | Novel inhibitors |